
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **September 30, 2017**

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: **001-37854**

Ekso Bionics Holdings, Inc.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of
incorporation or organization)

99-0367049
(I.R.S. Employer
Identification No.)

1414 Harbour Way South, Suite 1201
Richmond, CA
(Address of principal executive offices)

94804
(Zip Code)

(510) 984-1761
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted to its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer
(Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of registrant's common stock outstanding as of November 1, 2017 was 59,903,876.

Ekso Bionics Holdings, Inc.
Quarterly Report on Form 10-Q

Table of Contents

PART I. FINANCIAL INFORMATION	Page No.
<u>Item 1. Financial Statements</u>	<u>3</u>
<u>Condensed Consolidated Balance Sheets as of September 30, 2017 (unaudited) and December 31, 2016</u>	<u>3</u>
<u>Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2017 and 2016 (unaudited)</u>	<u>4</u>
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2017 and 2016 (unaudited)</u>	<u>5</u>
<u>Notes to Condensed Consolidated Financial Statements (unaudited)</u>	<u>6</u>
<u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>21</u>
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	<u>32</u>
<u>Item 4. Controls and Procedures</u>	<u>32</u>
PART II. OTHER INFORMATION	
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>33</u>
<u>Item 6. Exhibits</u>	<u>34</u>
<u>Signatures</u>	<u>34</u>

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Ekso Bionics Holdings, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except par value)

	September 30, 2017	December 31, 2016
	(unaudited)	(Note 2)
Assets		
Current assets:		
Cash	\$ 33,439	\$ 16,846
Accounts receivable, net	2,168	1,780
Inventories, net	2,378	1,556
Prepaid expenses and other current assets	2,097	502
Deferred cost of revenue, current	86	-
Total current assets	40,168	20,684
Property and equipment, net	2,301	2,435
Intangible assets, net	626	1,026
Goodwill	189	189
Other assets	121	91
Total assets	\$ 43,405	\$ 24,425
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 990	\$ 1,879
Accrued liabilities	2,746	3,556
Deferred revenues, current	1,242	825
Note payable, current	1,556	-
Other liabilities, current	58	54
Total current liabilities	6,592	6,314
Deferred revenue	685	805
Note payable	5,368	6,789
Warrant liabilities	767	3,546
Contingent consideration liability	248	217
Contingent success fee liability	13	116
Other non-current liabilities	65	107
Total liabilities	13,738	17,894
Commitments and contingencies (Note 15)		
Stockholders' equity:		
Convertible preferred stock, \$0.001 par value; 10,000 shares authorized; none issued and outstanding at September 30, 2017, and December 31, 2016, respectively	-	-
Common stock, \$0.001 par value; 71,429 shares authorized; 59,904 and 21,894 shares issued and outstanding as of September 30, 2017, and December 31, 2016, respectively	60	22
Additional paid-in capital	165,060	121,291
Accumulated other comprehensive (loss) income	(277)	79
Accumulated deficit	(135,176)	(114,861)
Total stockholders' equity	29,667	6,531
Total liabilities and stockholders' equity	\$ 43,405	\$ 24,425

The accompanying notes are an integral part of these condensed consolidated financial statements

Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2017	2016	2017	2016
Revenue:				
Device and related	\$ 1,587	\$ 1,495	\$ 4,862	\$ 11,003
Engineering services	10	101	38	631
Total revenue	<u>1,597</u>	<u>1,596</u>	<u>4,900</u>	<u>11,634</u>
Cost of revenue:				
Device and related	1,045	1,123	3,593	9,078
Engineering services	8	70	15	452
Total cost of revenue	<u>1,053</u>	<u>1,193</u>	<u>3,608</u>	<u>9,530</u>
Gross profit	<u>544</u>	<u>403</u>	<u>1,292</u>	<u>2,104</u>
Operating expenses:				
Sales and marketing	3,226	2,735	9,563	8,151
Research and development	1,986	2,216	7,491	6,586
General and administrative	2,414	2,318	7,430	8,271
Restructuring	-	-	665	-
Change in fair value, contingent liabilities	(16)	-	(191)	-
Total operating expenses	<u>7,610</u>	<u>7,269</u>	<u>24,958</u>	<u>23,008</u>
Loss from operations	<u>(7,066)</u>	<u>(6,866)</u>	<u>(23,666)</u>	<u>(20,904)</u>
Other income (expense), net:				
Gain (loss) on revaluation of warrant liabilities	1,814	(1,620)	4,851	3,030
Loss on repurchase of warrants	(1,067)	-	(1,067)	-
Interest income (expense) and other, net	(16)	8	(262)	(20)
Total other income (expense), net	<u>731</u>	<u>(1,612)</u>	<u>3,522</u>	<u>3,010</u>
Net loss	<u>(6,335)</u>	<u>(8,478)</u>	<u>(20,144)</u>	<u>(17,894)</u>
Less: Preferred deemed dividend	-	(3,016)	-	(10,345)
Net loss applicable to common stockholders	<u>(6,335)</u>	<u>(11,494)</u>	<u>(20,144)</u>	<u>(28,239)</u>
Foreign currency translation adjustments	(122)	(17)	(356)	(6)
Comprehensive loss	<u>\$ (6,457)</u>	<u>\$ (11,511)</u>	<u>\$ (20,500)</u>	<u>\$ (28,245)</u>
Net loss per share applicable to common stockholders, basic	<u>\$ (0.18)</u>	<u>\$ (0.60)</u>	<u>\$ (0.73)</u>	<u>\$ (1.67)</u>
Weighted average number of shares of common stock outstanding, basic	<u>34,720</u>	<u>19,005</u>	<u>27,425</u>	<u>16,888</u>
Net loss per share applicable to common stockholders, diluted	<u>\$ (0.18)</u>	<u>\$ (0.60)</u>	<u>\$ (0.73)</u>	<u>\$ (1.78)</u>
Weighted average number of shares of common stock outstanding, diluted	<u>34,720</u>	<u>19,005</u>	<u>27,425</u>	<u>17,595</u>

The accompanying notes are an integral part of these condensed consolidated financial statements

Ekso Bionics Holdings, Inc.
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Nine months ended September 30,	
	2017	2016
Operating activities:		
Net loss	\$ (20,144)	\$ (17,894)
Adjustments to reconcile net loss to net cash used in operating activities		
Gain on change in fair value of warrant liabilities	(4,851)	(3,030)
Stock-based compensation expense	1,755	2,552
Depreciation and amortization	1,304	1,381
Provision for doubtful accounts	100	-
Amortization of deferred rent	10	(27)
Accretion of final payment fee of debt	72	-
Amortization of debt discounts	63	-
Gain on change in fair value of contingent liabilities	(72)	-
Loss on repurchase of warrants	1,067	-
Unrealized gain on foreign currency transactions	(425)	-
Changes in operating assets and liabilities:		
Accounts receivable	(488)	(131)
Inventories	(1,239)	(1,026)
Note receivable	-	(75)
Prepaid expense and other assets	(1,618)	(94)
Deferred costs of revenue	(86)	4,498
Accounts payable	(750)	(1,335)
Accrued liabilities	(577)	1,279
Deferred revenues	297	(6,653)
Net cash used in operating activities	<u>(25,582)</u>	<u>(20,555)</u>
Investing activities:		
Acquisition of property and equipment	(353)	(728)
Net cash used in investing activities	<u>(353)</u>	<u>(728)</u>
Financing activities:		
Proceeds from issuance of common stock and warrants, net	42,463	14,694
Principal payments on note payable	(46)	(58)
Fees paid related to issuance of convertible preferred stock	-	(173)
Proceeds from exercise of stock options	42	74
Net cash provided by financing activities	<u>42,459</u>	<u>14,537</u>
Effect of exchange rate changes on cash	69	(6)
Net increase (decrease) in cash	16,593	(6,752)
Cash at beginning of period	16,846	19,552
Cash at end of period	<u>\$ 33,439</u>	<u>\$ 12,800</u>
Supplemental disclosure of non-cash activities		
Transfer of property and equipment to inventory	\$ 417	\$ 167
Repurchase of warrants and share issuance	\$ 2,245	\$ -
April 2017 warrant issuance	\$ 3,301	\$ -
Supply earn-out	\$ 189	\$ -
Sales earn-out	\$ 47	\$ -
Cumulative retrospective adjustment to retained earnings for ASU 2016-09 adoption	\$ 171	\$ -

The accompanying notes are an integral part of these condensed consolidated financial statements

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

1. Organization

Description of Business

Ekso Bionics Holdings, Inc. (the “Company”) is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the Company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The Company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO”.

All common stock share and per share amounts have been adjusted to reflect the one-for-seven reverse stock split completed on May 4, 2016. See *Note 12, Capitalization and Equity Structure – Reverse Stock Split*.

Liquidity and Going Concern

As of December 31, 2016, the Company had an accumulated deficit of \$114,861 and cash on hand of \$16,846. Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of this technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. The Company has also recognized significant non-cash losses in previous periods associated with the revaluation of certain securities, which have contributed significantly to its accumulated deficit. In the nine months ended September 30, 2017, the Company used \$25,582 of cash in its operations.

In 2017, management has taken several actions to alleviate the substantial doubt about the Company’s ability to continue as a going concern that existed as of the date of issuance of the December 31, 2016 consolidated financial statements, including, but not limited to, the following:

- streamlining its operations and reducing its workforce by approximately 27 employees to lower operating expenses and reduce cash burn;
- conducting a registered direct offering of 3,732 shares of its common stock for net proceeds of \$10,919; and
- conducting a rights offering, which resulted in the issuance of an aggregate of 13,465 shares of its common stock for net proceeds of \$13,179 and concurrently selling 20,535 shares of its common stock to the backstop investor in a private placement for proceeds of \$20,535.

With cash on hand of \$33,439 as of September 30, 2017, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these condensed consolidated financial statements.

The Company’s actual capital requirements may vary significantly and will depend on many factors. The Company plans to continue its investments (i) in its clinical, sales and marketing initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation market, (ii) in its research, development and commercialization activities with respect to an Ekso robotic exoskeleton for home use, and/or (iii) in the development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company may require significant additional financing in the future, which the Company intends to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by us could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to further reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2016, which included an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern in the report of our independent registered public accounting firm, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") and therefore, omit certain information and footnote disclosure necessary to present the financial statements in accordance with generally accepted accounting principles in the United States ("GAAP"). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which was filed with the SEC on March 15, 2017. The results of operations for the three months and nine months ended September 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.

Going Concern

The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with Accounting Standards Codification 205-40. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable.

Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of September 30, 2017 and December 31, 2016.

Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.

As of September 30, 2017, we had one customer with an accounts receivable balance totaling 10% or more of our total accounts receivable (13%) compared with three customers as of December 31, 2016 (18%, 16% and 11%).

In the three months ended September 30, 2017, we had one customer with sales of 10% or more of total revenue (16%), compared with one customer in the three months ended September 30, 2016 (15%). In the nine months ended September 30, 2017 and 2016, we had no customers with sales of 10% or more of total revenue.

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

Medical Device Revenue and Cost of Revenue Recognition

The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor and overhead in connection with the manufacture and assembly of these units.

When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service, and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company's follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, the amount of the arrangements was recognized as revenue and cost of revenue over a three-year period on a straight-line basis, while all service expenses, whether or not covered by the Company's original warranty, extended warranty contracts, or neither, were recognized as incurred.

Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs to allow the Company to separate its multiple element arrangements into two distinct units of accounting: (1) the device, associated software, original manufacturer warranty and training if required, and (2) extended support and maintenance. As a result, in the first quarter of 2016, the Company began to recognize revenue related to its sales transactions on a multiple element approach in which revenue is recognized upon the delivery of the separate elements to the customer. Revenue relating to the undelivered elements is deferred using the relative selling price method, which allocates revenue to each element using the estimated selling prices for the deliverables when vendor-specific objective evidence or third-party evidence is not available. For sales on or after January 1, 2016, revenue and associated cost of revenue of medical devices is recognized when delivered, or training has been completed, if required. Revenue for extended maintenance and support agreements is recognized on a straight-line basis over the contractual term of the agreement, which typically ranges from one to four years. As a result of this change, the Company recognized medical device revenue previously deferred at December 31, 2015 of \$6,517 and associated cost of revenue of \$4,159, resulting in additional gross profit, reduction in net loss from operations, and reduction of net loss applicable to common stockholders of \$2,358, or \$0.13 per share, in its results of operations for the nine months ended September 30, 2016. In addition, the Company recorded \$212 for warranty expenses and a one-time charge of \$911 for a planned preventative maintenance and upgrade program associated with the devices it had sold prior to 2016 in the same period.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, *Revenue from Contracts with Customers*. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued an update, ASU No. 2015-14, *Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date*, to defer the effective date of this update by one year. In April 2016, the FASB issued a further update, ASU No. 2016-10 *Revenue from Contracts with Customers (Topic 606) Identifying Performance Obligations and Licensing*. ASU 2016-10 clarifies that contractual provisions that explicitly or implicitly require an entity to transfer control of additional goods or services to a customer should be distinguished from contractual provisions that explicitly or implicitly define the attributes of a single promised license. In May 2016, the FASB issued a further update, ASU No. 2016-12 *Revenue from Contracts with Customers (Topic 606) Narrow-Scope Improvements and Practical Expedients*. ASU 2016-12 clarifies key areas concerning: (1) assessment of collectability, (2) presentation of sales taxes and other similar taxes collected from customers, (3) non-cash consideration, (4) contract modifications at transition, (5) completed contracts at transition, and (6) disclosing the accounting change in the period of adoption. The updated standard becomes effective for the Company in the first quarter of fiscal year 2018. The Company has identified the existing contracts likely to fall under ASC 606 and plans to adopt this guidance on January 1, 2018 applying the modified-retrospective approach.

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)* which will require lessees to recognize assets and liabilities for leases with lease terms of more than 12 months. For finance leases, a lessee is required to: (1) recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position, (2) recognize interest on the lease liability separately from amortization of the right-of-use asset in the statement of comprehensive income, and (3) classify repayments of the principal portion of the lease liability within financing activities and payments of interest on the lease liability and variable lease payments within operating activities in the statement of cash flows. For operating leases, a lessee is required to: (1) recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position, (2) recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis, and (3) classify all cash payments within operating activities in the statement of cash flows. The new guidance is effective for fiscal years beginning after December 15, 2018. The Company is evaluating the impact that ASU 2016-02 will have on its consolidated financial statements and related disclosures.

In January 2017, the FASB issued ASU No. 2017-04, *Simplifying the Test for Goodwill Impairment*. ASU 2017-04 eliminated the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, entities are required to record an impairment charge based on the excess of the carrying amount over its fair value. The new standard will be effective for the Company beginning January 1, 2020 and early adoption is permitted. The Company does not expect the impact of adopting ASU 2017-04 to be material on its consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, *Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting* (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 will be effective for public companies for fiscal years beginning after December 15, 2017, including interim periods. Early adoption is permitted. The Company is evaluating the effect that ASU 2017-09 will have on its consolidated financial statements and related disclosures.

Recently Adopted Accounting Standards

In March 2016, the FASB issued ASU No. 2016-09 *Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting*. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions for public companies, including: (1) income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. The amendments in this update are effective for annual periods beginning after December 15, 2016. Effective January 1, 2017, the Company adopted ASU 2016-09 and elected to change its accounting policy to account for forfeitures as they occur to more closely align compensation expense to services provided. The change was applied on a modified retrospective basis with a cumulative effect adjustment to retained earnings of \$171 as of January 1, 2017.

3. Accumulated Other Comprehensive (Loss) Income

The change in accumulated other comprehensive (loss) income presented on the condensed consolidated balance sheets and the impact of significant amounts reclassified from accumulated other comprehensive (loss) income on information presented in the condensed consolidated statements of operations and comprehensive loss for the nine months ending September 30, 2017 are reflected in the table below, net of tax:

	Foreign Currency Translation
Balance at December 31, 2016	\$ 79
Other comprehensive loss before reclassification	(356)
Balance at September 30, 2017	<u>\$ (277)</u>

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

4. Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:

- **Level 1**—Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
- **Level 2**—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- **Level 3**—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.

The Company's fair value hierarchies for its financial assets and liabilities which require fair value measurement are as follows:

	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
September 30, 2017				
Liabilities				
Warrant liabilities	\$ 767	\$ -	\$ -	\$ 767
Contingent consideration liability	\$ 248	\$ -	\$ -	\$ 248
Contingent success fee liability	\$ 13	\$ -	\$ -	\$ 13
December 31, 2016				
Liabilities				
Warrant liability	\$ 3,546	\$ -	\$ -	\$ 3,546
Contingent consideration liability	\$ 217	\$ -	\$ -	\$ 217
Contingent success fee liability	\$ 116	\$ -	\$ -	\$ 116

The following table sets forth a summary of the changes in the fair value of the Company's Level 3 financial liabilities for the nine months ended September 30, 2017, which were measured at fair value on a recurring basis:

	<u>Warrant Liabilities</u>	<u>Contingent Consideration Liability</u>	<u>Contingent Success Fee Liability</u>
Balance at December 31, 2016	\$ 3,546	\$ 217	\$ 116
Initial fair value of April 2017 Warrants	3,301	-	-
Revaluation of 2015 and April 2017 Warrants	(4,851)	-	-
Repurchase of April 2017 Warrants	(2,296)	-	-
Loss on repurchase of April 2017 Warrants	1,067	-	-
Loss on increase in fair value of obligation	-	31	-
Gain on decrease in fair value of obligation	-	-	(103)
Balance at September 30, 2017	<u>\$ 767</u>	<u>\$ 248</u>	<u>\$ 13</u>

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

Refer to Note 12 Capitalization and Equity Structure – Warrants for additional information regarding the repurchase and valuation of warrants.

5. Inventories, net

Inventories consisted of the following:

	<u>September 30, 2017</u>	<u>December 31, 2016</u>
Raw materials	\$ 1,516	\$ 1,193
Work in progress	-	198
Finished goods	964	267
	<u>2,480</u>	<u>1,658</u>
Less: inventory reserve	(102)	(102)
Inventories, net	<u>\$ 2,378</u>	<u>\$ 1,556</u>

6. Deferred Revenues

In connection with our medical devices, the Company often receives cash payments before the earnings process is complete. The Company records the payments as customer deposits until a device is shipped to the customer. The cash received is recorded as a component of deferred revenue.

Deferred revenues consisted of the following:

	<u>September 30, 2017</u>	<u>December 31, 2016</u>
Customer deposits and advances	\$ 48	\$ 47
Deferred rental income	65	60
Deferred extended maintenance and support	1,814	1,523
Total deferred revenues	<u>1,927</u>	<u>1,630</u>
Less current portion	(1,242)	(825)
Deferred revenues, non-current	<u>\$ 685</u>	<u>\$ 805</u>
Deferred medical device unit costs	\$ 86	\$ -
Less current portion	(86)	-
Deferred cost of revenue, non-current	<u>\$ -</u>	<u>\$ -</u>

7. Intangible Assets

The following table reflects the amortization of the purchased intangible assets as of September 30, 2017:

	<u>Cost</u>	<u>Accumulated Amortization</u>	<u>Net</u>
Developed technology	\$ 1,160	\$ (709)	\$ 451
Customer relationships	70	(43)	27
Customer trade name	380	(232)	148
	<u>\$ 1,610</u>	<u>\$ (984)</u>	<u>\$ 626</u>

Estimated future amortization for the remainder of 2017 and 2018, is \$135 and \$491, respectively.

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

8. Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2017	December 31, 2016
Salaries, benefits and related expenses	\$ 1,648	\$ 2,349
Device maintenance	259	483
Device warranty	136	203
Professional fees	363	56
Clinical trials	99	35
Equipois earn-out	-	355
Other	241	75
Total	<u>\$ 2,746</u>	<u>\$ 3,556</u>

A reconciliation of the changes in the current portion of maintenance and warranty liabilities for the period ended September 30, 2017 is as follows:

	Maintenance	Warranty	Total
Balance at December 31, 2016	\$ 483	\$ 203	\$ 686
Incurred costs	(224)	(67)	(291)
Balance at September 30, 2017	<u>\$ 259</u>	<u>\$ 136</u>	<u>\$ 395</u>

9. Restructuring

In May of 2017, the Company streamlined its operations and reduced its workforce by approximately 27 employees to lower operating expenses and reduce cash burn. The Company will focus its efforts on the commercialization of its proprietary Ekso GT for rehabilitation and exploration of potential strategic alternatives to accelerate product and market adoption of our industrial products, on our own and/or in collaboration with others. The restructuring plan was completed by the end of the second quarter of 2017.

The Company recorded restructuring expense of \$665 for the nine months ended September 30, 2017, which was comprised of employee severance payments of \$480, stock compensation expense of \$186 related to restricted stock units issued to terminated employees (*refer to Note 13, Stock-Based Compensation for issuance of restricted stock units*) and other severance related benefits. As of September 30, 2017, \$8 of the restructuring expenses was included in other liabilities, current on the Company's condensed consolidated balance sheet.

The following table summarizes accrued restructuring costs as of September 30, 2017:

	Employee Severance and Other Benefits
Balance at December 31, 2016	\$ -
Restructuring charges	665
Cash payments	(471)
Stock based compensation expense	(186)
Balance at September 30, 2017	<u>\$ 8</u>

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

10. Long-Term Debt

In December 2016, the Company entered into a loan agreement and received \$7,000 that bears interest on the outstanding daily balance at a floating per annum rate equal to the 30-day U.S. LIBOR rate plus 5.41%. The Company may further borrow an additional \$3,000. The loan agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.

The Company is required to pay accrued interest on the current loan on the first day of each month through and including January 1, 2018, or July 1, 2018 if the additional \$3,000 is drawn. Commencing on February 1, 2018, or August 1, 2018 if the additional \$3,000 is drawn, the Company is required to make equal monthly payments of principal, together with accrued and unpaid interest. The principal balance of the current loan amortizes ratably over 36 months and matures on January 1, 2021, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. In addition, a final payment of \$245 will be due on the maturity date, of which \$72 has accreted as of September 30, 2017, to be paid in 2021 and is included as a component of note payable in the Company's condensed consolidated balance sheets.

In December 2016, and pursuant to the loan agreement, the Company entered into a success fee agreement with the lender under which the Company agreed to pay the lender a \$250 success fee upon the first to occur of any of the following events: (a) a sale or other disposition by the Company of all or substantially all of its assets; (b) a merger or consolidation of the Company into or with another person or entity, where the holders of the Company's outstanding voting equity securities immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity immediately following the consummation of such merger or consolidation; or (c) the closing price per share for the Company's common stock being \$8.00 or more for five successive business days. The estimated fair value of the success fee was determined using the Binomial Lattice Model and was recorded as a discount to the debt obligation. The fair value of the contingent success fee is re-measured each reporting period with any adjustments in fair value being recognized in the condensed consolidated statements of operations and comprehensive loss. The success fee is classified as a liability on the condensed consolidated balance sheets. At September 30, 2017, the fair value of the contingent success fee liability was \$13.

The loan agreement includes a liquidity covenant requiring that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least three months of "Monthly Cash Burn," which is the Company's average monthly net income (loss) for the trailing six-month period plus certain expenses and plus the average monthly principal due and payable on interest-bearing liabilities in the immediately succeeding three-month period. Such amount was determined to be \$6,984 as of September 30, 2017, the most current determination, with the amount subject to change on a month-to-month basis. Pursuant to the restructuring and in anticipation of the Rights Offering, the lender and the Company executed an amendment to the loan agreement on August 3, 2017, which suspended the minimum liquidity requirement until September 16, 2017. At September 30, 2017, with cash on hand of \$33,439, the Company was compliant with this liquidity covenant and all other covenants.

The final payment fee, debt issuance costs, and the initial fair value of the success fee combined with the stated interest result in an effective annual interest rate of 9.20% for three-month period ended September 30, 2017 and 8.96% for the nine-month period ended September 30, 2017. The final payment fee, the initial fair value of the success fee and debt issuance costs will be accreted and amortized, respectively, to interest expense using the effective interest method over the life of the loan.

The following table presents scheduled principal payments of our long-term debt and final payment fee as of September 30, 2017:

Period	Amount
2017	\$ -
2018	2,139
2019	2,333
2020	2,333
2021	440
Total principal payments	7,245
Less final payment fee, discount and issuance cost	(321)
Long-term debt, net	<u>\$ 6,924</u>
Current portion	1,556
Long-term portion	5,368
Long-term debt, net	<u>\$ 6,924</u>

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

11. Lease Obligations

The Company renewed its operating lease agreement in May 2017 for its headquarters and manufacturing facility in Richmond, California. Following renewal, the lease term will expire in May 2022.

In July 2017, the Company entered into an operating lease agreement having a five-year lease term for an office in Hamburg, Germany. The Company has an option to extend the lease for another five-year term. The Company continues to lease an office in Freiburg with plans to sublease the office by the end of 2017.

In August 2015, the Company entered into a long-term capital lease obligation for equipment. The aggregate principal of the lease is \$166, with an interest rate of 4.7%, minimum monthly payments of \$3 and a July 1, 2020 maturity. This capital lease is classified as a component of other liabilities, current and other non-current liabilities in the condensed consolidated balance sheets.

The Company estimates future minimum payments as of September 30, 2017 to be the following:

Period	Capital Lease	Operating Lease
2017 – remainder	\$ 9	\$ 149
2018	37	605
2019	37	620
2020	22	632
2021	-	556
Thereafter	-	251
Total minimum payments	105	\$ 2,813
Less interest	(7)	
Present value minimum payments	98	
Less current portion	(33)	
Long-term portion	\$ 65	

Rent expense under the Company's operating leases was \$138 and \$101 for the three months ended September 30, 2017, and 2016, respectively, and \$347 and \$299 for the nine months ended September 30, 2017, and 2016, respectively.

12. Capitalization and Equity Structure

Reverse Stock Split

After the close of the stock market on May 4, 2016, the Company effected a 1-for-7 reverse split of its common stock. As a result, all common stock share amounts included in this filing have been retroactively reduced by a factor of seven, and all common stock per share amounts have been increased by a factor of seven, with the exception of our common stock par value. Common stock outstanding, including the issuance of new shares of common stock as a result of the conversion of preferred stock and the exercise of stock options and warrants, was affected by the 1-for-7 reverse split.

Common Stock

In April 2017, the Company sold in a registered direct offering an aggregate of 3,732 shares of its common stock, par value \$0.001 per share, and warrants to purchase 1,866 shares of common stock. The aggregate net proceeds of the transaction were approximately \$10,919.

Rights Offering

In August of 2017, the Company commenced a \$34,000 rights offering (the “Rights Offering”) to its existing stockholders and certain warrant holders of the Company on the record date of August 10, 2017. The subscription price was \$1.00 per share and each subscription right provided 1.1608 shares of the Company’s common stock plus an oversubscription right, subject to availability. Concurrent with the rights offering, the Company entered into a backstop investment agreement with Puissance Capital Management. The backstop investment agreement contemplated the purchase of any unsubscribed shares from the Rights Offering under the same terms. The common shares issued to the backstop investor were unregistered and subject to a cap of 40% of the Company’s total outstanding shares.

In connection with the rights offering, the Company entered into a Warrant Repurchase and Amendment Agreement (“Repurchase Agreement”) with all of the holders of the warrants issued in April 2017 (the “April 2017 Warrants”). Under the Repurchase Agreement, the Company agreed to repurchase the April 2017 Warrants from each holder at a price of \$1.23 per underlying share. The Company’s obligation to repurchase the warrants was subject to the warrant holder’s participation in the Rights Offering. The Repurchase Agreement also permitted the holders of the April 2017 Warrants to use all or a portion of the consideration received as a result of the Company’s repurchase of the April 2017 Warrants to pay the subscription price for the exercise of their subscription rights in the Rights Offering. Upon the closing of the Rights Offering the Company repurchased 1,866 warrant shares and applied consideration of \$2,245 to the subscribed shares in the Rights Offering.

The Company sold an aggregate of 13,465 shares of its common stock to existing stockholders and certain warrant holders in the Rights Offering for gross proceeds of \$13,465, which after deducting expenses, totaling approximately \$286, resulted in net proceeds of \$13,179 from the Rights Offering; and 20,535 shares of its common stock to the backstop investor in a private placement in conjunction with the Rights Offering for gross proceeds of \$20,535. Of the \$286 in direct issuance costs, warrants with a fair value of \$131 have been issued to an information agent. The warrants are classified as equity in the statement of stockholders’ equity. The Company intends to use the proceeds of the offering to broaden its footprint in Asia, support research, development and commercialization activities, and for working capital.

Warrants

Warrant shares outstanding as of December 31, 2016 and September 30, 2017 were as follows:

Source	Exercise Price	Term (Years)	December 31, 2016	Issued	Repurchased⁽¹⁾	Expired	September 30, 2017
Information Agent Warrants	\$ 1.50	3	-	200	-	-	200
April 2017 Warrants	\$ 4.10	5	-	1,866	(1,866)	-	-
2015 Warrants	\$ 3.74	5	1,634	-	-	-	1,634
2014 PPO and Merger							
Placement agent warrants	\$ 7.00	5	426	-	-	-	426
Bridge warrants	\$ 7.00	3	371	-	-	(371)	-
PPO warrants	\$ 14.00	5	1,078	-	-	-	1,078
Pre-2014 warrants	\$ 9.66	9-10	88	-	-	-	88
			<u>3,597</u>	<u>2,066</u>	<u>(1,866)</u>	<u>(371)</u>	<u>3,426</u>

(1) April 2017 Warrants were repurchased at a price of \$1.23 per underlying share, as a result of the Rights Offering.

Information Agent Warrants

In September 2017, in connection with the Rights Offering in August of 2017, the Company issued warrants to purchase 200 shares of the Company’s common stock with an exercise price of \$1.50 to an information agent (the “Information Agent Warrants”). The Information Agent Warrants became exercisable immediately upon issuance. These warrants were recorded in stockholders’ equity on the Company’s condensed consolidated balance sheet.

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

April 2017 Warrants

In April 2017, the Company issued the April 2017 Warrants to purchase 1,866 shares of the Company's common stock with an exercise price of \$4.10 per share. The April 2017 Warrants were to become exercisable six months following the issuance date and were to expire five years from the date they became exercisable. The April 2017 Warrants contained a put-option provision. Under this provision, while the April 2017 Warrants were outstanding, if the Company entered into a Fundamental Transaction, defined as a merger, consolidation or similar transaction, the Company or any successor entity would, at the option of each warrant holder, exercisable at any time within 30 days after the consummation of the Fundamental Transaction, purchase the warrant from the holder exercising such option by paying to the holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder's warrant on the date of the consummation of the Fundamental Transaction. Because of this put-option provision, a portion of the proceeds from the sale of common stock in the registered direct offering was recorded as a warrant liability equal to the fair value of the warrants on the date of issuance and the April 2017 Warrants were marked to market at each reporting date. Issuance costs allocated to the April 2017 Warrants were \$185 and were expensed as financing costs on the date of issuance. All of the issued and outstanding April 2017 warrants were repurchased at a price of \$1.23 per underlying share, as a result of the August 2017 Rights Offering. As of September 30, 2017, none of the April 2017 Warrants remained outstanding.

2015 Warrants

In December 2015, the Company issued warrants to purchase 2,122 shares with an exercise price of \$3.74 per share (the "2015 Warrants"). The 2015 Warrants contain a put-option provision. Under this provision, while the 2015 Warrants are outstanding, if the Company enters into a Fundamental Transaction, defined as a merger, consolidation or similar transaction, the Company or any successor entity will, at the option of each warrant holder, exercisable at any time within 30 days after the consummation of the Fundamental Transaction, purchase the warrant from the holder exercising such option by paying to the holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder's warrant on the date of the consummation of the Fundamental Transaction. Because of this put-option provision, the 2015 Warrants are classified as a liability and are marked to market at each reporting date.

The warrant liability related to the 2015 Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black Scholes Option Pricing Model to measure the fair value of the 2015 warrants as of September 30, 2017:

Current share price	\$	1.21
Conversion price	\$	3.74
Risk-free interest rate		1.66%
Term (years)		3.25
Volatility of stock		95%

13. Stock-based Compensation

In June 2017, the Company stockholders approved an amendment of the Company's Amended and Restated 2014 Equity Incentive Plan (the "2014 Plan") to increase the number of shares available for grant by 1,000 shares. The total shares authorized for grant under the 2014 Plan is 4,714, of which 534 are available for future grant as of September 30, 2017.

Stock Options

The following table summarizes information about the Company's stock options outstanding at September 30, 2017, and activity during the nine months then ended:

	Stock Awards	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Balance as of December 31, 2016	2,477	\$ 6.50		
Options granted	835	\$ 2.00		
Options exercised	(73)	\$ 0.58		
Options forfeited	(162)	\$ 6.79		
Options cancelled	(105)	\$ 6.63		
Balance as of September 30, 2017	<u>2,972</u>	\$ 5.36	7.57	\$ 33
Vested and expected to vest at September 30, 2017	<u>2,972</u>	\$ 5.36	7.57	\$ 33
Exercisable as of September 30, 2017	<u>1,515</u>	\$ 6.35	5.99	\$ 30

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

As of September 30, 2017, total unrecognized compensation cost related to unvested stock options was \$3,647. This amount is expected to be recognized as stock-based compensation expense in the Company's condensed consolidated statements of operations and comprehensive income over the remaining weighted average vesting period of 2.35 years.

The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions:

	<u>Three months ended</u> <u>September 30,</u>		<u>Nine months ended September</u> <u>30,</u>	
	<u>2017</u>	<u>2016</u>	<u>2017</u>	<u>2016</u>
Dividend yield	—	—	—	—
Risk-free interest rate	1.83% - 1.94%	1.25% - 1.26%	1.83% - 2.29%	1.24% - 1.78%
Expected term (in years)	5-6	6	5 - 9	5-10
Volatility	87%	80%	82%	79%

Restricted Stock Units

Beginning in 2017, the Company issued restricted stock units ("RSUs"), to employees and non-employees as permitted by the 2014 Plan. Each restricted stock unit corresponds to one share of the Company's common stock and becomes issuable upon vesting. The fair value of restricted stock units is determined based on the closing price of the Company's common stock on the date of grant.

In April 2017, the Company granted a total of 153 RSUs to certain executive officers, which vest over four years, with 25% becoming exercisable on each yearly anniversary of the date of grant.

In May 2017, the Company granted a total of 120 RSUs to terminated employees, 115 of which vested in September 2017. The remaining RSUs are scheduled to vest in January 2018.

In August 2017, the Company granted a total of 451 RSUs to continuing employees, which will fully vest on March 31, 2018.

RSU activity for the nine months ended September 30, 2017 is summarized below:

	<u>Number of Shares</u>	<u>Weighted- Average Grant Date Fair Value</u>
Unvested as of January 1, 2017	-	
Granted	724	\$ 1.64
Vested	115	\$ 1.59
Forfeited	-	
Unvested at September 30, 2017	<u>609</u>	

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

Compensation Expense

Total stock-based compensation expense related to options and RSUs granted to employees and non-employees is included in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three months ended September 30,		Nine months ended September 30,	
	2017	2016	2017	2016
Sales and marketing	\$ 187	\$ 103	\$ 365	\$ 541
Research and development	103	127	287	499
General and administrative	360	221	917	1,512
Restructuring charges	-	-	186	-
	<u>\$ 650</u>	<u>\$ 451</u>	<u>\$ 1,755</u>	<u>\$ 2,552</u>

Employee Stock Purchase Plan

In June 2017, the Company's stockholders approved the Employee Stock Purchase Plan (the "2017 ESPP"). Under the 2017 ESPP, the Company reserved 500 shares of common stock for issuance, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The 2017 ESPP allows eligible employees to purchase shares of the Company's common stock at a discount through payroll deductions of up to 25% of their eligible compensation, subject to any plan limitations. The 2017 ESPP provides for six-month offering periods. At the end of each offering period, employees can purchase shares at 85% of the lower of the fair market value of the Company's common stock on the first trading day of the offering period or on the last trading day of the offering period. As of September 30, 2017, enrollment in the plan had not commenced.

401(k) Plan Share Match

In August 2017, the Company's Board of Directors approved a match benefit to the Ekso Bionics 401(k) plan (the "401(k) Plan") in the form of shares of the Company's common stock. The Company will make a matching contribution to the 401(k) Plan in an amount equal to 100% of each eligible employee's elected deferral (up to the statutory limit) for the year ending December 31, 2017 and equal to 50% of each employee's elected deferral for each year thereafter.

14. Income Taxes

There were no material changes to the unrecognized tax benefits in the nine months ended September 30, 2017, and the Company does not expect significant changes to unrecognized tax benefits through the end of the fiscal year. Because of the Company's history of tax losses, all years remain open to tax examination.

15. Commitments and Contingencies

Material Contracts

The Company enters various license, research collaboration and development agreements which provide for payments to the Company for government grants, fees, cost reimbursements typically with a markup, technology transfer and license fees, and royalty payments on sales.

The Company has two license agreements with the Regents of the University of California to maintain exclusive rights to certain patents. Pursuant to those license agreements, the Company is required to pay 1% of net sales of products sold to entities other than the U.S. government and, in the event of a sub-license, the Company will owe 21% of license fees and must pass through 1% of the sub-licensee's net sales of products sold to entities other than the U.S. government. The agreements also stipulate minimum annual royalties of \$50.

In connection with acquisition of Equipois, the Company assumed the rights and obligations of Equipois under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants the Company an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company will be required to pay the developer a single-digit royalty on net receipts, subject to a \$50 annual minimum royalty requirement.

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

Contingencies

In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company's condensed consolidated financial statements.

16. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

	Three months ended September 30,		Nine months ended September 30,	
	2017	2016	2017	2016
Numerator:				
Net loss applicable to common stockholders				
Basic	\$ (6,335)	\$ (11,494)	\$ (20,144)	\$ (28,239)
Adjustment for revaluation of warrant liability	-	-	-	(3,030)
Diluted	\$ (6,335)	\$ (11,494)	\$ (20,144)	\$ (31,269)
Denominator:				
Weighted-average number of shares, basic	34,720	19,005	27,425	16,888
Effect of dilutive warrants	-	-	-	707
Weighted-average numbers of shares, diluted	34,720	19,005	27,425	17,595
Net loss per share, basic	<u>\$ (0.18)</u>	<u>\$ (0.60)</u>	<u>\$ (0.73)</u>	<u>\$ (1.67)</u>
Net loss per share, diluted	<u>\$ (0.18)</u>	<u>\$ (0.60)</u>	<u>\$ (0.73)</u>	<u>\$ (1.78)</u>

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	Three months ended September 30,		Nine months ended September 30,	
	2017	2016	2017	2016
Options to purchase common stock	2,972	2,474	2,972	2,474
Restricted stock	609	-	609	-
Warrants for common stock	3,426	4,085	3,426	1,963
Total common stock equivalents	<u>7,007</u>	<u>6,559</u>	<u>7,007</u>	<u>4,437</u>

17. Segment Disclosures

The Company has three reportable segments: Medical Devices, Industrial Sales, and Engineering Services. The Medical Devices segment designs and engineers technology for, and commercializes, manufactures, and sells exoskeletons for applications in the medical markets. The Industrial Sales segment designs, engineers, commercializes, and sells exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. Engineering Services generates revenue principally from collaborative research and development service arrangements, technology license agreements, and government grants where the Company uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities such as the National Science Foundation and the Defense Advanced Research Projects Agency.

The Company evaluates performance and allocates resources based on segment gross profit margin. The reportable segments are each managed separately because they serve distinct markets, and one segment provides a service and the others manufacture and distribute unique products. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(\$ and share amounts in thousands, except per share amounts)
(Unaudited)

Segment reporting information is as follows:

	<u>Device and Related</u>			<u>Engineering</u>	<u>Total</u>
	<u>Medical</u>	<u>Industrial</u>	<u>Total</u>	<u>Services</u>	
Three months ended September 30, 2017					
Revenue	\$ 1,320	\$ 267	\$ 1,587	\$ 10	\$ 1,597
Cost of revenue	880	165	1,045	8	1,053
Gross profit	<u>\$ 440</u>	<u>\$ 102</u>	<u>\$ 542</u>	<u>\$ 2</u>	<u>\$ 544</u>
Three months ended September 30, 2016					
Revenue	\$ 1,089	\$ 406	\$ 1,495	\$ 101	\$ 1,596
Cost of revenue	833	290	1,123	70	1,193
Gross profit	<u>\$ 256</u>	<u>\$ 116</u>	<u>\$ 372</u>	<u>\$ 31</u>	<u>\$ 403</u>
Nine months ended September 30, 2017					
Revenue	\$ 3,692	\$ 1,170	\$ 4,862	\$ 38	\$ 4,900
Cost of revenue	2,786	807	3,593	15	3,608
Gross profit	<u>\$ 906</u>	<u>\$ 363</u>	<u>\$ 1,269</u>	<u>\$ 23</u>	<u>\$ 1,292</u>
Nine months ended September 30, 2016					
Revenue	\$ 10,321	\$ 682	\$ 11,003	\$ 631	\$ 11,634
Cost of revenue	8,543	535	9,078	452	9,530
Gross profit	<u>\$ 1,778</u>	<u>\$ 147</u>	<u>\$ 1,925</u>	<u>\$ 179</u>	<u>\$ 2,104</u>

Geographic information for revenue based on location of customers is as follows:

	<u>Three months ended September</u>		<u>Nine months ended September</u>	
	<u>30,</u>	<u>2016</u>	<u>30,</u>	<u>2016</u>
United States	\$ 1,130	\$ 1,243	\$ 3,092	\$ 6,940
All Other	467	353	1,808	4,694
	<u>\$ 1,597</u>	<u>\$ 1,596</u>	<u>\$ 4,900</u>	<u>\$ 11,634</u>

18. Related Party Transactions

On September 19, 2017, Ted Wang, Ph.D, was appointed to the Board of Directors and as a member of the Nominating and Governance Committee of the Board. Dr. Wang is the Chief Investment Officer and a founder of Puissance Capital Management LP. Dr. Wang was elected as a director following his nomination to the Board by Puissance Cross-Border Opportunities II LLC (“Puissance”), a stockholder of the Company and an affiliate of Puissance Capital Management LP. Puissance served as the committed investor in connection with the Company’s recently completed rights offering, in connection with which Puissance purchased 20,535 shares of the Company’s common stock for an aggregate purchase price of \$20,535. Following completion of the rights offering, Puissance held approximately 34% of the Company’s issued and outstanding shares.

Prior to Dr. Wang’s appointment to the Board, the Company entered into a one-year consulting agreement with Angel Pond Capital LLC (“Angel Pond”), an entity affiliated with Puissance. Angel Pond will assist the Company with strategic positioning in the Asia Pacific region, including the introduction to potential strategic and capital partner(s) and the development of strategic partnership(s) for the sale and manufacture of the Company’s products in that market. In the third quarter of 2017, the Company made aggregate payments of \$2,150 to Angel Pond representing consulting services for one year. These fees are recognized ratably to expense over the one-year period.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion of our financial condition and results of operation in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2016.

This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements include all statements other than statements of historical facts contained or incorporated by reference in this quarterly report, including statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC, (iv) our beliefs regarding the potential for commercial opportunity for exoskeleton technology in general and our exoskeleton products in particular, (v) our beliefs regarding potential clinical and other health benefits of our medical devices, and (vi) the assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv) or (v) above. The words "may," "might," "would," "should," "could," "project," "estimate," "pro-forma," "predict," "potential," "strategy," "anticipate," "attempt," "develop," "plan," "help," "believe," "continue," "intend," "expect," "future," and similar expressions (including the negative of any of the foregoing) are intended to identify forward-looking statements.

The following factors, among others, including those described in the section titled "Risk Factors" included in our Annual Report on Form 10-K for the year ended December 31, 2016, could cause our future results to differ materially from those expressed in the forward-looking information:

- our ability to obtain adequate financing to fund operations and to develop or enhance our technology;
- our ability to obtain or maintain regulatory approval to market the Company's medical devices;
- the anticipated timing, cost and progress of the development and commercialization of new products or services, and improvements to our existing products, and related impacts on our profitability and cash position;
- our ability to effectively market and sell our products and expand our business, both in unit sales and product diversification;
- our ability to achieve broad customer adoption of our products and services;
- our ability to complete clinical trials on a timely basis and that completed clinical trials will be sufficient to support commercialization of our products;
- existing or increased competition;
- rapid changes in technological solutions available to our markets;
- volatility with our business, including long and variable sales cycles, which could have a negative impact on our results of operations for any given quarter;
- our ability to obtain or maintain patent protection for the Company's intellectual property;
- the scope, validity and enforceability of our and third party intellectual property rights;
- significant government regulation of medical devices and the healthcare industry;
- our customers' ability to get third party reimbursement for our products and services associated with them;
- our failure to implement our business plan or strategies;
- our ability to retain or attract key employees;
- stock volatility or illiquidity;
- our ability to maintain adequate internal controls over financial reporting; and
- overall economic and market conditions.

Although we believe that the assumptions underlying the forward-looking statements and forward-looking information contained herein are reasonable, any of the assumptions could be inaccurate, and therefore such statements and information included in this Quarterly Report on Form 10-Q may not prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements and forward-looking information included herein, the inclusion of such statements and information should not be regarded as a representation by us or any other person that the results or conditions described in such statements and information or that our objectives and plans will be achieved. Such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Overview

The Company designs, develops and sells exoskeleton technology to augment human strength, endurance and mobility. The Company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. The Company has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods.

Today, the Company's medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient's central nervous system to take advantage of a person's neuroplasticity to maximize a patient's recovery.

For able-bodied industrial workers, last year we introduced a new product innovation for aerial work platforms (AWP) and scaffolding, the EksoZeroG, which is intended to significantly improve workforce productivity while dramatically reducing workplace related injuries in order to keep workers healthy, strong, and safe. EksoZeroG is a mobile arm mount that makes heavy tools feel weightless and enables workers to be more productive and safer. In 2017, we are focusing on increasing sales of the EksoZeroG by pursuing alternative channels such as rental agreements with construction equipment and heavy tool providers. In addition, we believe there is additional mid-to-long-term potential in the industrial markets, and accordingly, we will continue to explore potential strategic alternatives to accelerate product and market adoption of our industrial products, on our own and/or in collaboration with others.

The Company believes the commercial opportunity for exoskeleton technology adoption is accelerating as a result of recent advancements in material technologies, electronic and electrical engineering, control technologies, and sensor and software development. Taken individually, many of these advancements have become ubiquitous in peoples' everyday lives. The Company believes it has learned how to integrate these existing technologies and wrap the result around a human being efficiently, elegantly and safely, supported by an industry leading intellectual property portfolio. The Company further believes it can do so across a broad spectrum of applications, from persons with lower limb paralysis to able-bodied users.

Recent Business Developments

Restructuring

In May of 2017, the Company streamlined its operations and reduced its workforce by approximately 27 employees to lower operating expenses and reduce cash burn. The Company will focus its efforts on the commercialization of its proprietary Ekso GT for rehabilitation and its exoskeleton offerings for industrial applications. The restructuring plan was completed by the end of the second quarter of 2017. The Company recorded restructuring expense of \$0.7 million for the nine months ended September 30, 2017, comprised of employee severance payments, stock compensation expense related to restricted stock units issued to terminated employees, and other severance related benefits. (Refer to *Note 9, Restructuring* of the Condensed Consolidated Financial Statements).

Equity Financings

In April 2017, the Company sold in a registered direct offering an aggregate of 3,732,356 shares of its common stock, par value \$0.001 per share, and warrants to purchase 1,866,178 shares of common stock with an exercise price of \$4.10 per share. The aggregate net proceeds of the transaction were approximately \$10.9 million. The warrants were to become exercisable six months following the issuance date and were to expire five years from the date they became exercisable.

In August of 2017, the Company commenced a \$34.0 million rights offering to its existing stockholders and certain warrant holders of the Company on the record date of August 10, 2017. The subscription price was \$1.00 per share and each subscription right gave holders the right to purchase 1.1608 shares of the Company's common stock plus an oversubscription right, subject to availability. Concurrent with the rights offering, the Company entered into a backstop investment agreement with Puissance Capital Management. The backstop investment agreement contemplated the purchase of any unsubscribed shares from the Rights Offering under the same terms. The common shares issued to the backstop investor were unregistered and subject to a cap of 40% of the Company's total outstanding shares.

In connection with the rights offering, the Company entered into the Repurchase Agreement with all of the holders of the April 2017 Warrants. Under the Repurchase Agreement, the Company agreed to repurchase the April 2017 Warrants from each holder at a price of \$1.23 per underlying share, subject to the warrant holder's participation in the Rights Offering. The Repurchase Agreement also permitted the holders of the April 2017 Warrants to use all or a portion of the consideration received as a result of the Company's repurchase of the April 2017 Warrants to pay the subscription price for the exercise of their subscription rights in the Rights Offering. Upon the closing of the Rights Offering the Company repurchased 1,866,178 warrant shares and applied consideration of \$2.2 million to the subscribed shares in the Rights Offering.

The Company sold an aggregate of 13,465,102 shares of its common stock to existing stockholders and certain warrant holders in the Rights Offering for gross proceeds of \$13.5 million, which after deducting expenses totaling approximately \$0.3 million, resulted in net proceeds of \$13.2 million from the Rights Offering; and 20,534,898 shares of its common stock to the backstop investor in a private placement in conjunction with the Rights Offering for gross proceeds of \$20.5 million. Of the \$0.3 million in direct issuance costs, warrants with a fair value of \$0.1 million have been issued to an information agent. The warrants are classified as equity in the statement of stockholders' equity. The Company intends to use the proceeds of the offering to broaden its footprint in Asia, support research, development and commercialization activities, and for working capital.

Clinical Update

The Company's strategy continues to be to expand clinical data associated with robotic exoskeleton use and, in particular, Ekso GT. To date, there have been 62 studies announced utilizing the Ekso GT, including 35 completed studies and 27 ongoing studies, encompassing a total of nearly 1,500 patients. This includes the first Company-sponsored clinical trial, which is led by Professor Dylan Edwards, Ph.D., P.T., of The Burke Medical Research Institute. The study, entitled WISE (Walking Improvement for SCI with Exoskeletons), evaluates improvement in independent gait speeds of Spinal Cord Injury ("SCI") patients undergoing rehabilitation with the Ekso GT and compares it to both conventional therapy and a control group. The US-based, multi-center study has been initiated at seven rehabilitation centers and seeks to enroll approximately 160 people with chronic incomplete SCI.

The Company also continues to work with investigators who have independently initiated large clinical trials to study the use of the Ekso GT, including: a Kessler Foundation study that is enrolling acute stroke patients in a grant-funded randomized, controlled trial with the goal of demonstrating the benefits of early intervention with gait therapy using the Ekso GT; a registry headed up by the Rehabilitation Institute of Chicago focusing on the clinical efficacy of the Ekso GT in both SCI and stroke survivors; and a study being conducted by the Moritz Klink entitled The MOST Study (Mobility improved after stroke when a robotic device was used in comparison to physical therapy) investigating the impact of gait training with the Ekso GT on functional independence of 80 patients with impaired gait as a consequence of stroke when compared to conventional physiotherapy alone.

In January 2017, the National Institute for Health and Care Excellence, a public body of the Department of Health in the United Kingdom, released a Medtech Innovation Briefing (MIB) on the Ekso GT robotic exoskeleton, the first and only such briefing on exoskeletons. The MIB highlights the innovative aspect of Ekso Bionics' proprietary SmartAssist software, which differentiates Ekso GT from other available wearable exoskeletons. The MIB notes that SmartAssist technology allows physiotherapists to strategically target aspects of a patient's gait by providing different amounts of support to each leg, effectively personalizing the treatment for each patient's specific needs.

Sales and Marketing Update - Rehabilitation

In conjunction with our FDA clearance in April 2016, including the only approved label in the industry that includes patients with hemiplegia due to stroke, we completed a full review of our sales and marketing efforts. We have begun to broaden the launch of our Ekso GT and our go-to-market plan in the US and in Europe, including an increase in marketing campaigns to educate the market on the benefits of stroke rehabilitation using exoskeletons, and arranging product demonstrations with various stakeholders at our target customers.

Today we have four direct salespersons, one direct sales representative and a distributor manager for over 10 distributors in Europe, as well as a sales operations manager that supports the efforts of both regions. This sales team is supported by 10 physical therapists to provide customer demonstrations and training, and six sales operation and customer service personnel. Over the past several quarters the Company has endeavored to better understand its customer's decision cycle for adopting the Company's new technology, in order to optimize the pace of placements and adoption, and has piloted a number of alternative approaches for trial, sales, and rental options. For example, in the United States, we have piloted a short-term (three to six months) customer rental with an option to convert to purchase or long-term rental to place units with customers, which in several cases has been more effective than pursuing sales through the standard capital purchase budget cycle. Given the track record of converting previous rentals to sales, we could see these short term rentals in the United States and other operating rental options facilitate expansion of the Company's rehabilitation program, while also allowing us to reduce the timeline to place our Ekso GT units.

Recently we launched our Centers of Excellence program in both the US and Europe, a unique peer-to-peer program through which some of our key customers and thought leaders share their knowledge and experience with potential and new customers. The program spans the operational areas of clinical, sales and marketing to bring together the user experience and share it with new customers to facilitate adoption and utilization. These Centers of Excellence will work with our integrated sales and marketing teams and will be available to prospective customers/partners to discuss the clinical, business and financial merits of using the Ekso GT as a tool in rehabilitation. These Centers of Excellence complement the more than 175 hospitals and clinics that already have incorporated Ekso GT in their rehabilitation programs.

Ekso Bionics has been granted 35 Continuing Competence Units, through the Federation of State Board of Physical Therapy (FSBPT), for physical therapists that successfully complete the Ekso GT training program. The FSBPT recognized the comprehensive overview of gait analysis, robotic technology integration into gait training, and interactive learning through guided instruction during our training program.

Regulatory Status

On April 4, 2016, the Company received clearance from the FDA to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with the device's labeling. On July 19, 2016, the Company received clearance from the FDA to expand/clarify the indications and labeling to expressly include individuals with hemiplegia due to stroke who have upper extremity function of at least 4/5 in only one arm. The Company's prior cleared indications for use statement required that individuals with hemiplegia due to stroke have upper extremity function of at least 4/5 in both arms.

The US government regulates the medical device industry through various agencies, including but not limited to, the FDA, which administers the federal Food, Drug and Cosmetic Act. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the extent of control deemed necessary to ensure the device's safety and effectiveness. Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are deemed to pose the least risk and are subject only to general controls applicable to all devices, such as requirements for device labeling, premarket notification, and adherence to the FDA's current good manufacturing practice requirements, as reflected in its Quality System Regulation ("QSR"). Class II devices are intermediate risk devices that are subject to general controls and may also be subject to special controls such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general or special controls, and include life-sustaining, life-supporting, or implantable devices, and devices not "substantially equivalent" to a device that is already legally marketed. Most Class I devices, and some Class II devices are exempted by regulation from the 510(k) clearance requirement and can be marketed without prior authorization from FDA. Class I and Class II devices that have not been so exempted are eligible for marketing through the 510(k) clearance pathway. By contrast, devices placed in Class III generally require premarket approval, or PMA, prior to commercial marketing.

The Company believes that prior to April 4, 2016, the Company's Ekso GT robotic exoskeleton had been appropriately marketed as a Class I 510(k) exempt Powered Exercise Equipment device since February 2012. On June 26, 2014, the FDA announced the creation of a new product classification for Powered Exoskeleton devices. On October 21, 2014, the FDA published the summary for the new Powered Exoskeleton classification and designated it as being Class II, which requires the clearance of a 510(k) notice.

On October 21, 2014, concurrent with the FDA's publication of the reclassification of Powered Exoskeleton devices, the FDA issued the Company an "Untitled Letter" which informed the Company in writing of the agency's belief that this new product classification applied to our Ekso GT device. On December 24, 2014, the Company filed a 510(k) notice for the Ekso robotic exoskeleton, which was accepted by the FDA for substantive review on July 29, 2015. As discussed above, the Company received FDA clearance to market its Ekso GT in accordance with the device's labeling on April 4, 2016.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Our estimates form the basis for our judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimate that are reasonably likely to occur, could materially impact the condensed consolidated financial statements. We believe that our critical accounting policies reflect the more significant estimates and assumptions used in the preparation of the condensed consolidated financial statements.

The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor, and overhead in connection with the manufacture and assembly of these units.

When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain service and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company's follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, the amount of the arrangements were recognized as revenue and cost of revenue over a three-year period on a straight-line basis, while all service expenses, whether or not covered by the Company's original warranty, extended warranty contracts, or neither, were recognized as incurred.

Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs to allow the Company to bifurcate its sales transactions into two separate units of accounting: (1) the device, associated software, original manufacturer warranty and training, if required, and (2) extended support and maintenance. As a result, in the first quarter of 2016, the Company began to recognize revenue related to its sales transactions on a multiple element approach in which revenue is recognized upon the delivery of the separate elements to the customer. Revenue relating to the undelivered elements is deferred using the relative selling price method, which allocates revenue to each element using the estimated selling prices for the deliverables when vendor-specific objective evidence or third-party evidence is not available. For sales on or after January 1, 2016, revenue and associated cost of revenue of medical devices is recognized when delivered, or training has been completed, if required. Revenue for extended maintenance and support agreements is recognized on a straight-line basis over the contractual term of the agreement, which typically ranges from one to four years. As a result of this change, the Company recognized medical device revenue previously deferred at December 31, 2015 of \$6.5 million and associated cost of revenue of \$4.2 million, resulting in additional gross profit, reduction in net loss from operations, and reduction of net loss applicable to common stockholders of \$2.4 million, or \$0.13 per share, in its results of operations in the three-month period ended March 31, 2016. In addition, the Company recorded \$0.2 million for warranty expenses and a one-time charge of \$0.9 million for a planned preventative maintenance and upgrade program associated with the devices it had sold prior to 2016 in the same time period.

Adoption of New Accounting Policy

Effective January 1, 2017, the Company adopted Accounting Standards Update ("ASU") 2016-09 *Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting*. In adopting ASU 2016-09, the Company elected to change its accounting policy to account for forfeitures as they occur to more closely align compensation expense to services provided. The change was applied on a modified retrospective basis with a cumulative effect adjustment to retained earnings as of January 1, 2017 of \$0.2 million.

Results of Operations

The following table presents our results of operations for the three months ended September 30 (in thousands):

	Three months ended September 30,			% Change
	2017	2016	Change	
Revenue:				
Device and related	\$ 1,587	\$ 1,495	\$ 92	6%
Engineering services	10	101	(91)	-90%
Total revenue	1,597	1,596	1	0%
Cost of revenue:				
Device and related	1,045	1,123	(78)	-7%
Engineering services	8	70	(62)	-89%
Total cost of revenue	1,053	1,193	(140)	-12%
Gross profit	544	403	141	35%
Operating expenses:				
Sales and marketing	3,226	2,735	491	18%
Research and development	1,986	2,216	(230)	-10%
General and administrative	2,414	2,318	96	4%
Change in fair value, contingent liabilities	(16)	-	(16)	--
Total operating expenses	7,610	7,269	341	5%
Loss from operations	(7,066)	(6,866)	(200)	3%
Other income (expense), net:				
Gain (loss) on revaluation of warrant liabilities	1,814	(1,620)	3,434	-212%
Loss on repurchase of warrants	(1,067)	-	(1,067)	--
Interest income (expense) and other, net	(16)	8	(24)	-300%
Total other income (expense), net	731	(1,612)	2,304	-143%
Net loss	(6,335)	(8,478)	2,104	-25%
Less: Preferred deemed dividend	-	(3,016)	3,016	-100%
Net loss applicable to common stockholders	\$ (6,335)	\$ (11,494)	\$ 5,120	-45%

Revenue

Device and related increased \$0.1 million, or 6%, for the three months ended September 30, 2017, compared to the same period of 2016. This increase was made up of a \$0.2 million increase in medical device revenue, primarily due to a higher volume of medical device sales, partially offset by a \$0.1 million decrease in industrial device revenue.

As the Company did not have any substantial engineering projects for the three months ended September 30, 2017, the Company recognized an immaterial amount of engineering services revenues in the period. Engineering services revenue was \$0.1 million for the quarter ended September 30, 2016.

Gross Profit

Gross profit increased \$0.1 million, or 35%, for the three months ended September 30, 2017 compared to the same period of 2016, primarily due to higher sales of medical devices and a reduction in service costs.

Operating Expenses

Sales and marketing expenses increased \$0.5 million, or 18%, for the three months ended September 30, 2017, compared to the same period of 2016 primarily due to an increase in marketing efforts related to the commercialization of the Company's medical devices for rehabilitation and its exoskeleton offerings for industrial applications, and an increase in clinical research activity.

Research and development expenses decreased \$0.2 million, or 10%, for the three months ended September 30, 2017, compared to the same period of 2016 primarily due to decreased employment costs as a result of the reduction in workforce.

General and administrative expenses increased \$0.1 million, or 4%, for the three months ended September 30, 2017, compared to the same period of 2016 primarily due to an increase in business development related activities in Asia.

Change in fair value, contingent liabilities for the three months ended September 30, 2017, included changes of the fair value of the contingent consideration liability related to Equipois sales earnouts and contingent success fee liability related to the outstanding debt with lender.

Other Income, Net

Other income, net, increased \$2.3 million, or 143%, primarily related to the changes of fair value of warrant liabilities.

Gain on revaluation of warrant liabilities of \$1.8 million for the three months ended September 30, 2017 was associated with the revaluation of warrants issued in 2015 and April 2017, compared to a loss of \$1.6 million from the revaluation of warrants issued in 2015 for the three months ended September 30, 2016. The gains and losses on the revaluation of warrants are primarily driven by changes in the Company's stock price.

Loss on repurchase of warrants of \$1.1 million for the three months ended September 30, 2017, was associated with the difference in the fair value of the April 2017 Warrants on the date of repurchase and the repurchase price. There was no comparable amount during the same period in 2016.

Interest income (expense) and other, net in the three months ended September 30, 2017, included \$0.1 million of unrealized exchange gains partially offset by \$0.2 million interest expense associated with the \$7.0 million of debt obtained in December 2016. The Company had substantially no debt outstanding in 2016 and immaterial unrealized exchange gains.

Preferred Deemed Dividend

In the three months ended September 30, 2016, 3,867 shares of convertible preferred stock were converted into approximately 980,594 shares of common stock, resulting in a \$3.0 million non-cash preferred deemed dividend that related to the amortization of the discount associated with the warrants issued in December 2015.

The following table presents our results of operations for the nine months ended September 30 (in thousands):

	Nine months ended September 30,		Change	% Change
	2017	2016		
Revenue:				
Device and related	\$ 4,862	\$ 11,003	\$ (6,141)	-56%
Engineering services	38	631	(593)	-94%
Total revenue	4,900	11,634	(6,734)	-58%
Cost of revenue:				
Device and related	3,593	9,078	(5,485)	-60%
Engineering services	15	452	(437)	-97%
Total cost of revenue	3,608	9,530	(5,922)	-62%
Gross profit	1,292	2,104	(812)	-39%
Operating expenses:				
Sales and marketing	9,563	8,151	1,412	17%
Research and development	7,491	6,586	905	14%
General and administrative	7,430	8,271	(841)	-10%
Restructuring	665	-	665	--
Change in fair value, contingent liabilities	(191)	-	(191)	--
Total operating expenses	24,958	23,008	1,950	8%
Loss from operations	(23,666)	(20,904)	(2,762)	13%
Other income (expense), net:				
Gain on revaluation of warrant liabilities	4,851	3,030	1,821	60%
Loss on repurchase of warrants	(1,067)	-	(1,067)	--
Interest expense and other, net	(262)	(20)	(242)	1210%
Total other income (expense), net	3,522	3,010	512	17%
Net loss	(20,144)	(17,894)	(2,250)	13%
Less: Preferred deemed dividend	-	(10,345)	10,345	-100%
Net loss applicable to common stockholders	\$ (20,144)	\$ (28,239)	\$ 8,095	-29%

Revenue

Device and related revenue decreased \$6.1 million, or 56%, for the nine months ended September 30, 2017, compared to the same period of 2016 primarily due to the recognition of revenue during the nine months ended September 30, 2016 of \$6.5 million of previously deferred revenue resulting from a change of an accounting estimate (see Note 2 in the notes to our condensed consolidated financial statements under the caption *Basis of Presentation and Summary of Significant Accounting Policies and Estimates - Medical Device Revenue and Cost of Revenue Recognition*); partially offset by increased medical device sales.

We did not have any substantial engineering projects for the nine months ended September 30, 2017. Engineering services revenue was \$0.6 million for the nine months ended September 30, 2016.

Gross Profit

Gross profit decreased \$0.8 million, or 39%, for the nine months ended September 30, 2017 primarily due to \$2.4 million of gross profit from our change in accounting estimate related to revenue recognition during the nine months ended September 30, 2016 (see Note 2 in the notes to our condensed consolidated financial statements under the caption *Basis of Presentation and Summary of Significant Accounting Policies and Estimates - Medical Device Revenue and Cost of Revenue Recognition*); partially offset by increased medical device sales.

Operating Expenses

Sales and marketing expenses increased \$1.4 million, or 17%, for the nine months ended September 30, 2017, compared to the same period of 2016 primarily due to an increase in marketing efforts related to the commercialization of the Company's medical devices for rehabilitation and its exoskeleton offerings for industrial applications, an increase in clinical research activity, and increased average employee headcount notwithstanding the reduction in workforce in May 2017.

Research and development expenses increased \$0.9 million, or 14%, for the nine months ended September 30, 2017, compared to the same period of 2016 primarily due to labor being redirected to product innovation activities from billable engineering service projects which was recorded in cost of revenue, and increases in outside services and material purchases for the development of medical and industrial products, respectively.

General and administrative expenses decreased \$0.8 million, or 10%, for the nine months ended September 30, 2017, compared to the same period of 2016 primarily due to the absence of a \$0.8 million non-cash stock compensation charge in the nine months ended September 30, 2016 related to the modification of stock options that had been granted to the then Chief Executive Officer. In addition, the 2016 period included a \$0.3 million severance charge with respect to the departure of the then Chief Executive Officer. These decreases were partially offset by increased costs associated with business development activities in Asia.

Restructuring expense of \$0.7 million for the nine months ended September 30, 2017 includes employee severance payments of \$0.4 million, stock compensation expense of \$0.2 million related to restricted stock units issued to terminated employees, and \$0.1 million of other related severance related benefits.

Change in fair value, contingent liabilities of \$0.2 million for the nine months ended September 30, 2017, included the changes of the fair value of the contingent consideration liability related to Equipos sales earnouts and contingent success fee liability related to the outstanding debt with lender.

Other Income, Net

Gain on revaluation of warrant liabilities increased \$1.8 million, or 60%, for the nine months ended September 30, 2017, compared to the same period of 2016. We recorded a gain of \$4.9 million on the revaluation of warrant liabilities related to warrants issued in 2015 and 2017 for the nine months ended September 30, 2017, compared to a gain of \$3.0 million on the revaluation of warrant liabilities related to warrants issued in 2015 for the nine months ended September 30, 2016. Gains and losses on revaluation of warrants are primarily driven by changes in the Company's stock price.

Loss on repurchase of warrants of \$1.1 million for the nine months ended September 30, 2017, was associated with the difference in the fair value of the April 2017 Warrants on the date of repurchase and the repurchase price. There was no comparable amount during the same period in 2016.

Interest expense and other, net increased \$0.2 million, primarily due to interest expense associated with the \$7.0 million of debt obtained in December 2016. The Company had an insignificant amount of debt outstanding during the same period in 2016.

Preferred Deemed Dividend

In the nine months ended September 30, 2016, 13,263 shares of convertible preferred stock were converted into approximately 2,309,531 shares of common stock, resulting in a \$10.3 million non-cash preferred deemed dividend that related to the amortization of the discount associated with the warrants issued in December 2015. There was no comparable amount during the same period in 2017.

Financial Condition, Liquidity and Capital Resource

Since the Company's inception, it has devoted substantially all its efforts toward the development of exoskeletons for the medical, military and industrial markets, toward the commercialization of medical exoskeletons to rehabilitation centers and toward raising capital. Accordingly, the Company is in the early commercialization stage. The Company has financed its operations primarily through the issuance and sale of equity securities for cash consideration and convertible and promissory notes, as well as from government research grant awards and strategic collaboration payments.

Cash and Working Capital

Cash on hand at September 30, 2017 was \$33.4 million compared to \$16.8 million at December 31, 2016. For the nine months ended September 30, 2017, the Company used \$25.6 million of cash in operations compared to \$20.6 million for the nine months ended September 30, 2016.

Liquidity and Capital Resources

As of December 31, 2016, the Company had an accumulated deficit of \$114.9 million and cash on hand of \$16.8 million. Largely as a result of significant research and development activities related to the development of the Company's advanced technology and commercialization of this technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. The Company has also recognized significant non-cash losses in previous periods associated with the revaluation of certain securities, which have contributed significantly to its accumulated deficit. In the nine months ended September 30, 2017, the Company used \$25.6 million of cash in its operations.

In 2017, management has taken several actions to alleviate the substantial doubt about the Company's ability to continue as a going concern that existed as of the date of issuance of the December 31, 2016 consolidated financial statements, including, but not limited to, the following:

- streamlining its operations and reducing its workforce by approximately 27 employees to lower operating expenses and reduce cash burn;
- conducting a registered direct offering of 3,732,356 shares of its common stock for net proceeds of \$10.9 million; and
- conducting a rights offering, which resulted in the issuance of an aggregate of 13,465,102 shares of its common stock for net proceeds of \$13.2 million and concurrently selling 20,534,898 shares of its common stock to the backstop investor in a private placement for proceeds of \$20.5 million.

With cash on hand of \$33.4 million as of September 30, 2017, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period one year from the issuance of these condensed consolidated financial statements.

The Company's actual capital requirements may vary significantly and will depend on many factors. The Company plans to continue its investments (i) in its clinical, sales and marketing initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation market, (ii) in its research, development and commercialization activities with respect to an Ekso robotic exoskeleton for home use, and/or (iii) in the development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company may require significant additional financing in the future, which the Company intends to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by us could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to further reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.

Cash and Cash Equivalents

The following table summarizes the sources and uses of cash (in thousands). The Company held no cash equivalents for any of the periods presented.

	Nine months ended September 30,	
	2017	2016
Net cash used in operating activities	\$ (25,582)	\$ (20,555)
Net cash used in investing activities	(353)	(728)
Net cash provided by financing activities	42,459	14,537
Effect of exchange rate changes on cash	69	(6)
Net increase (decrease) in cash	16,593	(6,752)
Cash at the beginning of the period	16,846	19,552
Cash at the end of the period	\$ 33,439	\$ 12,800

Net Cash Used in Operating Activities

Net cash used in operations increased \$5.0 million, or 24%, for the nine months ended September 30, 2017, compared to the same period of 2016 primarily due to increases in cash expenditures toward marketing efforts related to the commercialization of the Company's medical devices for rehabilitation and exoskeleton offerings for industrial applications, business development activities in Asia, product innovation activities for the development of medical and industrial products, and clinical research activities. In addition, inventory levels of our industrial products increased primarily due to the timing of sales and preparation of a new product launch.

Net Cash Used in Investing Activities

Net cash used in investing activities decreased \$0.4 million for the nine months ended September 30, 2017, compared to the same period of 2016 primarily due to lower acquisitions of property and equipment related to our company-owned fleet of Ekso units used for demonstrations and loaned to current customers, partially offset by expenditures on our new enterprise resource planning system.

Net Cash Provided by Financing Activities

The net cash provided by financing activities of \$42.5 million for the nine months ended September 30, 2017 was driven by proceeds from the sale of common stock related to the Rights Offering in August 2017 and the equity financing in April 2017.

The net cash provided by financing activities for the nine months ended September 30, 2016 included proceeds from the sale of common stock related to the equity financing in August 2016, offset by expenses paid related to the December 2015 issuance of convertible preferred stock.

Contractual Obligations and Commitments

The following table summarizes our outstanding contractual obligations as of September 30, 2017, and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):

	Payments Due By Period:				
	Total	Less than One Year	1-3 Years	4-5 Years	After 5 Years
Term loan	\$ 8,117	\$ 1,991	\$ 5,093	\$ 1,033	\$ -
Facility operating lease	2,813	601	1,246	966	-
Capital lease	105	37	68	-	-
Total	\$ 11,035	\$ 2,669	\$ 6,407	\$ 1,999	\$ -

In addition to the table above, which reflects only fixed payment obligations, the Company has two license agreements to maintain exclusive rights to certain patents. Under these license agreements, the Company is required to pay 1% of net sales of products sold to entities other than the U.S. government. In the event of a sublicense, the Company will owe 21% of license fees and must pass through 1% of the sub-licensee's net sales of products sold to entities other than the U.S. government. The license agreements also stipulate minimum annual royalties of \$50,000 per year.

In connection with our acquisition of Equipois in December 2015, the Company assumed the rights and obligations of Equipois under a license agreement with the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants the Company an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company will be required to pay the developer a single-digit royalty on net receipts, subject to a \$50,000 annual minimum royalty requirement.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

We are exposed to market risks in the ordinary course of our business, including inflation risks.

We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.

In addition, we conduct business in foreign countries and have subsidiaries based in the United Kingdom and Germany. Accordingly, we are exposed to exchange rate risk. See Item 7A. Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2016.

Item 4. Controls and Procedures

Disclosure Controls and Procedures.

Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act")) as of the end of the period covered by this report. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

It should be noted that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment and makes assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. Management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On September 11, 2017, the Company issued and sold 20,534,898 shares of common stock to Puissance Cross-Border Opportunities II LLC (“Puissance Cross-Border Opportunities”) pursuant to a backstop purchase agreement dated July 19, 2017 entered into in connection with the Company’s Rights Offering. The backstop investment agreement provided for the purchase of any unsubscribed shares from the Rights Offering at a price of \$1.00 per share, subject to a cap of 40% of the Company’s total outstanding shares. The shares of common stock were issued in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).

Item 6. Exhibits

Exhibit Number	Description
<u>4.1</u>	<u>Form of Warrant issued pursuant to the amendment dated September 13, 2017 to the information agent agreement between the Company and Katalyst Securities LLC dated August 11, 2017 (incorporated by reference from Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed September 19, 2017).</u>
<u>31.1*</u>	<u>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.</u>
<u>31.2*</u>	<u>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.</u>
<u>32.1*</u>	<u>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
<u>32.2*</u>	<u>Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101*	The following financial statements from the Ekso Bionics Holdings, Inc. Quarterly Report on Form 10Q for the quarter ended September 30, 2017, formatted in Extensible Business Reporting Language ("XBRL"): <ul style="list-style-type: none">· unaudited condensed consolidated balance sheets;· unaudited condensed consolidated statements of operations and comprehensive loss;· unaudited condensed consolidated statement of cash flows;· notes to unaudited condensed consolidated financial statements;

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Ekso Bionics Holdings, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EKSO BIONICS HOLDINGS, INC.

Date: November 8, 2017

By: /s/ Thomas Looby
Thomas Looby
President and Chief Executive Officer

Date: November 8, 2017

By: /s/ Maximilian Scheder-Bieschin
Maximilian Scheder-Bieschin
Chief Financial Officer

(Duly Authorized Officer and Principal Financial and Accounting Officer)

CERTIFICATION

I, Thomas Looby, certify that:

- (1) I have reviewed this Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc.;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
- (4) The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and
- (5) The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.

Date: November 8, 2017

/s/ Thomas Looby
Thomas Looby
Principal Executive Officer

CERTIFICATION

I, Maximilian Scheder-Bieschin, certify that:

- (1) I have reviewed this Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc.;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
- (4) The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and
- (5) The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.

Date: November 8, 2017

/s/ Maximilian Scheder-Bieschin
Maximilian Scheder-Bieschin
Principal Financial Officer

**CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350**

In connection with the Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc. (the "Company"), for the quarterly period ended September 30, 2017 as filed with the Securities and Exchange Commission (the "Report"), I, Thomas Looby, President and Chief Executive Officer and principal executive officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Dated: November 8, 2017

/s/ Thomas Looby
Thomas Looby
Principal Executive Officer

**CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350**

In connection with the Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc. (the "Company"), for the quarterly period ended September 30, 2017 as filed with the Securities and Exchange Commission (the "Report"), I, Maximilian Scheder-Bieschin, Chief Financial Officer and principal financial officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Dated: November 8, 2017

/s/ Maximilian Scheder-Bieschin
Maximilian Scheder-Bieschin
Principal Financial Officer
